# Equillium, Inc.

**EQ**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001746466

# None

**No letter**

5 of 13 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $31.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, thin data; fortress balance sh...<br>not computable: distress |
| **Inputs computable** | 5 of 13 |
| **Graded from** | filings received through Mar 25, 2026<br>239 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026 |
| **Last close** | $1.09<br>2026-11-18; market equity $89.7M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 25, 2026*

We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact inducing anti-inflammatory cells and cytokines while reducing proinflammatory cells and cytokines and improving intestinal tissue barrier function and repair.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 83.4** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Accruals ratio | 1.2% | (6.7%) | | 83.4 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 40.9** | | | | | | |
| Altman Z double-prime | (12.18) | 0.31 | | 66.5 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 10.58x | 2.68x | | 15.3 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 85.3** | | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | | |
| *four annual observations are required; found 3* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 33.9% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | (25.9%) | 3.2% | | 90.2 | 663 | 2025-12-31 |
| Net share issuance, one year | 77.6% | 1.6% | | 80.4 | 625 | 2026-03-20 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 77.6% |
| Thin data | 5 of 13 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 50,036,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-11-18 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 15.2% | (1.7%) | 59 |
| Distance from 52-week high | (65.6%) | (30.2%) | 18 |
| EBIT to enterprise value | (52.7%) | 0.5% | 12 |
| Free cash flow yield | (25.2%) | 0.6% | 19 |
| Book value to price | 0.58 | 0.29 | 73 |
| Sales to price | 0.45 | 0.36 | 57 |
| Composite equity issuance, five years | 104.2% | 13.5% | 83 |
| Relative strength against the sector, log excess return | (0.03) | (0.19) | 59 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $53.3M |
| Operating cash flow, four quarters | -$15.4M |
| Months of runway | 41.6 |
| Days since last periodic filing | 7 (10-Q received Nov 12, 2026) |
| Median daily dollar volume, 63 sessions | $556,301 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$62.1M | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$62.4M | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 4 | total debt | us-gaap:LongTermDebt | $9.1M | 2022-12-31 | 2023-03-23 | 10-K | 23-009492 |
| 5 | book equity | us-gaap:StockholdersEquity | $31.9M | 2022-12-31 | 2025-03-27 | 10-K | 25-045726 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $59.1M | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 7 | total debt | us-gaap:LongTermDebt | $10.2M | 2021-12-31 | 2022-03-23 | 10-K | 22-004407 |
| 8 | book equity | us-gaap:StockholdersEquity | $66.5M | 2021-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $50.4M | 2021-12-31 | 2023-03-23 | 10-K | 23-009492 |
| 10 | net income | us-gaap:NetIncomeLoss | -$22.4M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$22.7M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 12 | assets | us-gaap:Assets | $31.9M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 13 | assets | us-gaap:Assets | $25.6M | 2024-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 14 | current assets | us-gaap:AssetsCurrent | $31.0M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $2.9M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$216.2M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 17 | operating income | us-gaap:OperatingIncomeLoss | -$23.6M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 18 | book equity | us-gaap:StockholdersEquity | $28.6M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 19 | liabilities | us-gaap:Liabilities | $3.3M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 20 | depreciation amortization | us-gaap:Depreciation | $118,000 | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $41.1M | 2024-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 22 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $36.1M | 2023-12-31 | 2025-03-27 | 10-K | 25-045726 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $15.8M | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $48,000 | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$19.0M | 2024-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $85,000 | 2024-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$21.8M | 2023-12-31 | 2025-03-27 | 10-K | 25-045726 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $50,000 | 2023-12-31 | 2025-03-27 | 10-K | 25-045726 |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.7M | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 30 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $279,000 | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 31 | depreciation amortization | us-gaap:Depreciation | $116,000 | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 32 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$22.4M | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 33 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 34 | current assets | us-gaap:AssetsCurrent | $25.0M | 2024-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 35 | current liabilities | us-gaap:LiabilitiesCurrent | $6.4M | 2024-12-31 | 2026-03-25 | 10-K | 26-124143 |
| 36 | assets | us-gaap:Assets | $50.5M | 2023-12-31 | 2025-03-27 | 10-K | 25-045726 |
| 37 | assets | us-gaap:Assets | $78.4M | 2022-12-31 | 2024-03-25 | 10-K | 24-035919 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 63,226,556 | 2026-03-20 | 2026-03-25 | 10-K | 26-124143 |
| 39 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 35,609,907 | 2025-03-20 | 2025-03-27 | 10-K | 25-045726 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.